# A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

> **NCT02240017** · PHASE2,PHASE3 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 46 (actual)

## Conditions studied

- Advanced Urothelial Cancer
- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Fractionated Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02240017
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-21
- **Primary completion:** 2018-04-10
- **Final completion:** 2019-07-15
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240017, "A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02240017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*